Jung M, Calassi R, Maruani J, Barnouin M C, Souilhac J, Poncelet M, Gueudet C, Emonds-Alt X, Soubrié P, Brelière J C
Sanofi Recherche, Neuropsychiatry Department, Montpellier, France.
Neuropharmacology. 1994 Feb;33(2):167-79. doi: 10.1016/0028-3908(94)90004-3.
SR 140333 (1-[2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl) piperidin-3-yl]ethyl]-4-phenyl-1-azonia-bicyclo[2.2.2]octane , chloride), a potent non peptide ligand of the substance P (SP) NK1 receptor subtype with high affinity for NK1 receptors from both rat cortical membranes and human IM9 cells (Ki = 0.02 nM and 0.01 nM, respectively) was studied in vivo on various effects induced by NK1 agonists in rats and mice. SR 140333 given intraperitoneally (i.p.) in mice antagonized dose-dependently and in a stereoselective manner the scratching responses induced by intracerebroventricular SP and septide (ID50 = 0.73 and 0.08 mg/kg, respectively) and the turning behavior elicited by intrastriatal SP and septide (ID50 = 0.07 and 0.06 mg/kg, respectively). This compound had little effect on the scratching responses and the turning behavior elicited by [Sar9, Met(O2)11]-SP. When SR 140333 was coadministered with the peptide agonist, the compound reduced the scratching responses elicited by SP, [Sar9, Met(O2)11]-SP and septide injected intrathecally (i.t.) in mice (ID50 = 72.0, 64.3 and 52.5 ng i.t., respectively). SR 140333 antagonized the salivation induced by SP, [Sar9, Met(O2)11]-SP and septide in rats (ID50 = 0.13, 0.18 and 0.09 mg/kg i.p., respectively). SR 140333 abolished the facilitation of the tail-flick reflex induced by noxious heat in rats (total reversal at 0.06 mg/kg, i.p.). This compound was also found to inhibit the turning behavior induced by intrastriatal apomorphine in mice (ID50 = 0.1 mg/kg, i.p.). In conclusion, these results indicate that SR 140333 behaves as a potent, selective and centrally active NK1 receptor antagonist.
SR 140333(1-[2-[3-(3,4-二氯苯基)-1-(3-异丙氧基苯基乙酰基)哌啶-3-基]乙基]-4-苯基-1-氮杂双环[2.2.2]辛烷,氯化物)是一种对P物质(SP)NK1受体亚型具有高亲和力的强效非肽类配体,对大鼠皮质膜和人IM9细胞的NK1受体均有高亲和力(Ki分别为0.02 nM和0.01 nM),对其在大鼠和小鼠体内由NK1激动剂诱导的各种效应进行了研究。在小鼠中腹腔注射(i.p.)SR 140333剂量依赖性且立体选择性地拮抗了脑室内注射SP和septide诱导的抓挠反应(ID50分别为0.73和0.08 mg/kg)以及纹状体内注射SP和septide引发的旋转行为(ID50分别为0.07和0.06 mg/kg)。该化合物对[Sar9, Met(O2)11]-SP诱导的抓挠反应和旋转行为影响很小。当SR 140333与肽类激动剂共同给药时,该化合物可降低鞘内注射(i.t.)SP、[Sar9, Met(O2)11]-SP和septide在小鼠中诱导的抓挠反应(ID50分别为72.0、64.3和52.5 ng i.t.)。SR 140333拮抗了大鼠中由SP、[Sar9, Met(O2)11]-SP和septide诱导的唾液分泌(ID50分别为0.13、0.18和0.09 mg/kg i.p.)。SR 140333消除了大鼠中由有害热诱导的甩尾反射的促进作用(腹腔注射0.06 mg/kg时完全逆转)。还发现该化合物抑制小鼠纹状体内注射阿扑吗啡诱导的旋转行为(ID50为0.1 mg/kg,i.p.)。总之,这些结果表明SR 140333表现为一种强效、选择性且具有中枢活性的NK1受体拮抗剂。